European Meeting on Hypertension and Cardiovascular Protection: BEAUTY Trial Insights
Explore the latest findings from the 26th European Meeting on Hypertension and Cardiovascular Protection in Paris, showcasing results from the BEAUTY trial regarding hypertension control and hemodynamic monitoring. Discover how impedance-guided therapy failed to improve central blood pressure and pulse wave velocity, despite significant reductions in other markers at 6 months.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
26thEuropean Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 BEAUTY Trial: Hypertension Control Not Improved with Hemodynamic Monitoring From ESH 2016 | LB 3: Pierre Boutouyrie, MD, PhD INSERM, Universit Paris Descartes, Paris, France Infomedica Conference Coverage* of 26thEuropean Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 * Infomedica is an independent medical education provider that produces medical information to healthcare professionals through conference coverage and online educational programs and activities. Powered by Infomedica
26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Overview Impedance-guided therapy with the Hotman device (IHM) did not improve central blood pressure (CBP) or pulse wave velocity (PWV) compared with control in new analysis of BEAUTY study Study designed to determine if a drug selection algorithm driven by data from noninvasive hemodynamic profiles would improve CBP or PWV CBP and PWV measured with applanation tonometry using Sphygmocor system 115 of the 167 patients in BEAUTY included in analysis aged 64 years, median 3 antihypertensive medications, average systolic blood pressure (SBP) with ambulatory monitoring 143 mmHg Powered by Infomedica 26th European Meeting on Hypertension and Cardiovascular Protection
26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Results at 6 Months Marked, significant reduction in central SBP in both groups, no between-group difference (Figure 1) Marked, significant reduction in central pulse pressure in both groups, no between-group difference (Figure 1) Slightly higher values for augmentation index with IHM, but no between-group difference No between-group difference for amplification, a measure of peripheral-central SBP Significant improvement in PWV with IHM, but no significant between-group difference after adjustment for within-trial SBP (Figure 2) Powered by Infomedica 26th European Meeting on Hypertension and Cardiovascular Protection
26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Figure 1. Changes in Central Systolic Blood Pressure in BEAUTY Study mmHg 150 p<0.001 versus baseline 140 Control IHM 130 p=0.96 120 110 IHM, integrated hemodynamic management. Baseline Month 1 Month 2 Month 4 Month 6 Powered by Infomedica 26th European Meeting on Hypertension and Cardiovascular Protection
26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Figure 2. Changes in Pulse Wave Velocity in BEAUTY Study m/s 15 14 13 Control IHM p=0.46 12 11 Baseline SBP: p<0.001 Within trial changes in SBP: p=0.02 10 IHM, integrated hemodynamic management. Baseline Month 1 Month 2 Month 4 Month 6 Powered by Infomedica 26th European Meeting on Hypertension and Cardiovascular Protection
26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 Conclusions Monitoring hemodynamic parameters with a predefined algorithm for drug selection did not improve CBP or PWV in patients with hypertension Similar improvements were observed for central blood pressure, wave reflections, and amplification, Changes in pulse wave velocity were parallel to improvements in blood pressure with each treatment approach Powered by Infomedica 26th European Meeting on Hypertension and Cardiovascular Protection
26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 BEAUTY Trial: Hypertension Control Not Improved with Hemodynamic Monitoring From ESH 2016 | LB 3: Pierre Boutouyrie, MD, PhD INSERM, Universit Paris Descartes, Paris, France Infomedica Conference Coverage* of 26th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13, 2016 * Infomedica is an independent medical education provider that produces medical information to healthcare professionals through conference coverage and online educational programs and activities. Powered by Infomedica
